Cancer Letters
Volume 253, Issue 1 , Pages 97-107 , 8 August 2007

PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells

  • Vesa Aaltonen

      Affiliations

    • Department of Anatomy and Cell Biology, University of Oulu, Oulu, Finland
    • ,
  • Jussi Koivunen

      Affiliations

    • Department of Anatomy and Cell Biology, University of Oulu, Oulu, Finland
    • ,
  • Matti Laato

      Affiliations

    • Department of Surgery, University of Turku, Turku, Finland
    • Department of Medical Biochemistry, University of Turku, Turku, Finland
    • ,
  • Juha Peltonen

      Affiliations

    • Department of Anatomy and Cell Biology, University of Oulu, Oulu, Finland
    • Department of Dermatology, University of Oulu, Oulu, Finland
    • Department of Anatomy, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland
    • Department of Dermatology, University of Turku, Turku, Finland
    • Corresponding Author InformationCorresponding author. Address: Department of Anatomy, University of Turku, Kiinamyllynkatu 10, 20520 Turku, Finland. Tel.: +358 2 3337350; fax: +358 2 3337352.

Received 9 November 2006 ,Accepted 15 January 2007.

References 

  1. Chau BN, Wang JY. Coordinated regulation of life and death by RB. Nat. Rev. Cancer. 2003;3:130–138
  2. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell. Biochem. 2004;91:223–231
  3. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004;3:513–519
  4. Blanes A, Rubio J, Martinez A, Wolfe HJ, Diaz-Cano SJ. Kinetic profiles by topographic compartments in muscle-invasive transitional cell carcinomas of the bladder: role of TP53 and NF1 genes. Am. J. Clin. Pathol. 2002;118:93–100
  5. Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, et al. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 2002;62:6973–6980
  6. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 2004;73:39–85
  7. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2001;2:21–32
  8. Smits VA, Medema RH. Checking out the G(2)/M transition. Biochim. Biophys. Acta. 2001;1519:1–12
  9. Peters JM. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol. Cell. 2002;9:931–943
  10. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene. 2004;23:2825–2837
  11. Yuspa SH. Cutaneous chemical carcinogenesis. J. Am. Acad. Dermatol. 1986;15:1031–1044
  12. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 1995;9:484–496
  13. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science. 1992;258:607–614
  14. Aaltonen V, Koivunen J, Laato M, Peltonen J. Heterogeneity of cellular proliferation within transitional cell carcinoma: correlation of protein kinase C {alpha}/{beta}I expression and activity. J. Histochem. Cytochem. 2006;
  15. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2005;
  16. Koivunen J, Aaltonen V, Koskela S, Lehenkari P, Laato M, Peltonen J. Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 2004;64:5693–5701
  17. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA. 2000;97:8542–8547
  18. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl. Acad. Sci. USA. 2001;98:10386–10391
  19. Biswas DK, Martin KJ, McAlister C, Cruz AP, Graner E, Dai SC, et al. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Res. 2003;63:290–295
  20. Kohn EA, Yoo CJ, Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 2003;63:31–35
  21. Tse AN, Schwartz GK. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 2004;64:6635–6644
  22. Sugiyama K, Shimizu M, Akiyama T, Tamaoki T, Yamaguchi K, Takahashi R, et al. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int. J. Cancer. 2000;85:703–709
  23. Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res. 1996;2:791–797
  24. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 2000;351:95–105
  25. Rieger KM, Little AF, Swart JM, Kastrinakis WV, Fitzgerald JM, Hess DT, et al. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br. J. Cancer. 1995;72:683–690
  26. Martiny-Baron G, Kazanietz MG, Mischak H, Blumberg PM, Kochs G, Hug H, et al. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J. Biol. Chem. 1993;268:9194–9197
  27. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ, Johannes FJ. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996;392:77–80
  28. Blagosklonny MV. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene. 2002;21:6249–6254
  29. Levesque AA, Kohn EA, Bresnick E, Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene. 2005;24:3786–3796
  30. Canman CE. Replication checkpoint: preventing mitotic catastrophe. Curr. Biol. 2001;11:R121–R124
  31. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001;15:2177–2196
  32. Wang XQ, Redpath JL, Fan ST, Stanbridge EJ. ATR dependent activation of Chk2. J. Cell Physiol. 2006;208:613–619
  33. Kohn EA, Ruth ND, Brown MK, Livingstone M, Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J. Biol. Chem. 2002;277:26553–26564

PII: S0304-3835(07)00018-3

doi: 10.1016/j.canlet.2007.01.011

Cancer Letters
Volume 253, Issue 1 , Pages 97-107 , 8 August 2007

Article Tools

* Image Usage & Resolution